MDS/MPN-U and CMML patients frequently carried mutations in epigenetic regulators (ASXL1, TET2) and RNA splicing genes (SF3B1, SRSF2, ZRSR2). This evidence concerns the gene SRSF2 and myeloproliferative neoplasm, unclassifiable.